Top Markets
Coin of the day
Sofiva Genomics Co.,Ltd. Sofiva Genomics Co.,Ltd.

Sofiva Genomics Co.,Ltd.

6615
Rangering i aksjer #29061
Sofiva Genomics Co.,Ltd., established in 2012 and based in Taipei, Taiwan,... Sofiva Genomics Co.,Ltd., established in 2012 and based in Taipei, Taiwan, offers a comprehensive range of genetic testing services to both domestic and international clients. The company's diverse diagnostic solutions are designed to support expectant parents, individuals with inherited conditions, and their families. Their extensive prenatal diagnostics include screenings for conditions such as thalassemia carrier status, various microdeletion syndromes, single-gene abnormalities, common chromosomal anomalies, and specific skeletal dysplasia mutations. They also provide multi-gene panel testing for inherited diseases, folate metabolism genetic analysis, carrier screening for spinal muscular atrophy (SMA) and Fragile X syndrome, congenital infection detection, preeclampsia risk assessment, maternal serum screening for Down syndrome, and karyotyping. Within the oncology sector, Sofiva Genomics delivers advanced cancer screenings, dynamic monitoring of tumor activity, and genetic evaluations for hereditary cancer predisposition. This includes specialized panels for women's cancers (breast, colon, ovarian, and endometrial), alongside human papillomavirus (HPV) screening. Furthermore, the company conducts genetic testing for rare diseases and provides specialized reproductive services such as preimplantation genetic diagnosis (PGD) and next-generation sequencing (NGS)-based preimplantation genetic screening (PGS). For newborns, their services encompass comprehensive "baby scans," screenings for hereditary sensorineural hearing loss, congenital central hypoventilation syndrome (CCHS), congenital cytomegalovirus (CMV) infection, and genetic risk assessment for atopic dermatitis. Beyond these specialized offerings, Sofiva Genomics also performs biochemical and chromosomal analyses, complemented by valuable advisory and support services for its clientele.
Aksjekurs
$1.08
Markedsverdi
$23.24M
Endring (1 dag)
0.59%
Endring (1 år)
6.39%
Land
TW
Handel Sofiva Genomics Co.,Ltd. (6615)

Kategori

P/E-forhold for Sofiva Genomics Co.,Ltd. (6615)
P/E-forhold per 2026 TTM: 0
Ifølge Sofiva Genomics Co.,Ltd. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Sofiva Genomics Co.,Ltd. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
31.59 -
US
35.83 -
US
- -
CN
-227.89 -
US
29.77 -
US
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.